엑소좀 치료제 : 시장 규모, 대상 환자층, 경쟁 구도 및 시장 예측(2036년)

Key Highlights:

• Exosome therapies face significant development and regulatory challenges due to the lack of standardized manufacturing, product characterization, and quality control methods. Variability in exosome composition, scalability constraints, and evolving regulatory expectations have limited late-stage clinical development, resulting in no exosome-based therapy receiving full regulatory approval in major markets despite growing clinical interest.
• Despite the absence of any fully approved exosome-based therapy, exosome therapeutics remain a promising next-generation biologic platform with broad potential across regenerative medicine, oncology, neurological, inflammatory, and rare diseases. The current landscape is driven by emerging candidates such as BRE-AD01, AGLE-102, and DB-2Q, with ongoing innovation focused on harnessing exosome-mediated regenerative and immunomodulatory mechanisms, alongside engineered exosomes for targeted delivery of proteins, nucleic acids, and gene-editing payloads to enhance therapeutic efficacy and precision.

DelveInsight's "Exosome Therapies Market Size, Target Population, Competitive Landscape & Market Forecast - 2036" report delivers an in-depth understanding of Exosome Therapies, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The Exosome Therapies market report provides insights around existing treatment practices in patients with Exosome Therapies, approved (if any) and emerging Exosome Therapies, market share of individual therapies, patient pool eligible for treatment with Exosome Therapies, along with current and forecasted 7MM Exosome Therapies market size from 2022-2036 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new Exosome Therapies in different geographies, along with insights on Exosome Therapies pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2022-2036

Exosome Therapies Overview

Exosome therapies are an emerging class of cell-free biologics that use naturally derived extracellular vesicles to deliver therapeutic cargo, including proteins and nucleic acids, to target cells. Their low immunogenicity, intrinsic biocompatibility, and targeted delivery potential position them as a promising platform for regenerative medicine and precision therapeutics across multiple disease areas.

Target Patient Pool Analysis

• According to Kaitlyn R. Chan et al., atopic dermatitis affects up to 20% of children and approximately 10% of adults worldwide, with a prevalence of 7.3% in the US. This substantial and growing patient population, combined with the chronic relapsing nature of the disease, makes atopic dermatitis one of the most attractive indications for exosome-based therapies, offering significant commercial potential for developers of next-generation biologics.
• As per National Organization for Rare Disorders (NORD) (2025), the birth prevalence of DMD is estimated to be 1 in every 3,500 live male births in the US.
• As per World Health Organization (WHO), the Global Burden of Diseases initiative estimates more than 230 million people globally have atopic dermatitis and that skin diseases are the fourth leading cause of non-fatal disability worldwide.
• According to published epidemiological estimates, Japan reports approximately 28,000 cases of acute respiratory distress syndrome (ARDS) annually, highlighting the substantial clinical burden of this life-threatening condition and the continued need for effective therapeutic interventions and critical care management.

Exosome Therapies Drug Chapters

The drug chapter segment of the Exosome Therapies report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the Exosome Therapies clinical trial details, pharmacological action, agreements and collaborations related to Exosome Therapies, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

Exosome Therapies Emerging Drugs

DB-2Q: Direct Biologics

DB-2Q is a mesenchymal stromal cell-derived exosome therapy designed to deliver bioactive extracellular vesicles that modulate immune responses and promote tissue repair. It is being investigated for inflammatory and respiratory disorders, with the aim of reducing excessive inflammation, supporting tissue regeneration, and improving clinical outcomes. It is currently in Phase III.

AGLE-102: Aegle Therapeutics

AGLE-102 is an allogeneic extracellular vesicle (exosome) therapy being developed by Aegle Therapeutics for inflammatory and regenerative disorders. Derived from mesenchymal stromal cells, it is designed to deliver bioactive molecules that modulate inflammation, promote tissue repair, and improve healing across multiple disease settings.

It is currently in Phase I/II.

In July 2025, Aegle Therapeutics appointed Scott Braunstein, M.D., as Chairman of its Board of Directors, strengthening the company's leadership as AGLE-102 advances through clinical development.

In March 2025, Aegle Therapeutics highlighted AGLE-102 as a first-in-class extracellular vesicle (EV) therapy for RDEB and emphasized the ongoing Phase I/IIa clinical trial evaluating the therapy in patients with RDEB.

BRE-AD01: BREXOGEN

BRE-AD01 is an adipose tissue-derived exosome therapy being developed by BREXOGEN for the treatment of atopic dermatitis. It is designed to leverage the immunomodulatory and regenerative properties of exosomes to reduce inflammation, restore skin barrier function, and improve clinical outcomes in patients with chronic inflammatory skin disease. It is currently in Phase I.

Recent Developments in the Exosome Therapies Market

• In July 2026, an FDA advisory committee voted 9-3 against the efficacy data for Deramiocel (CAP-1002) in Duchenne muscular dystrophy-associated cardiomyopathy, with the FDA's BLA decision expected by August 22, 2026. Earlier, in May 2026, Capricor Therapeutics filed legal action against Nippon Shinyaku to regain US commercialization rights for the therapy.
• In May 2026, BREXOGEN reported interim Phase I clinical data for BRE-AD01 at the Society for Investigative Dermatology (SID) 2026, demonstrating favorable safety and tolerability following a single subcutaneous dose, along with statistically significant improvements in EASI, IGA, and BSA scores through Week 8.
• In March 2026, BREXOGEN presented first-in-human Phase I data for BRE-AD01 at EAACI 2026, demonstrating that a single subcutaneous dose was well tolerated and produced durable clinical improvements through Week 8 in patients with moderate-to-severe atopic dermatitis.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on Exosome Therapies as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of Exosome Therapies, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

Exosome Therapies Market Outlook

This section will include details on changing Exosome Therapies market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

Exosome Therapies Drugs Uptake

This section focuses on the uptake rate of potential Exosome Therapies already launched and expected to be launched in the market during 2022-2036, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Exosome Therapies Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Exosome Therapies Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Exosome Therapies.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on Exosome Therapies' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on Exosome Therapies addressable patient pool
• A detailed review of the Exosome Therapies market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM Exosome Therapies market.
• Market Size of Inhibitors by therapies and indication will be provided

Exosome Therapies Report Key Strengths

• 11 Years Exosome Therapies Market Forecast
• The 7MM Coverage
• Exosome Therapies Competitive Landscape of current and emerging therapies
• Exosome Therapies Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician's perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• Exosome Therapies Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs:

• What was the Exosome Therapies total market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for Exosome Therapies market growth?
• Which KRAS Inhibitor is going to be the largest contributor by 2036?
• What is the market access and reimbursement scenario of Exosome Therapies?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Exosome Therapies Market.
• Understand the existing Exosome Therapies market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Exosome Therapies

4. Key Events

5. Exosome Therapies Market Overview At A Glance

• 5.1. Market Share (%) Distribution of Exosome Therapies By Therapy in 2025
• 5.2. Market Share (%) Distribution of Exosome Therapies By Therapy in 2036

6. Background And Overview

7. Target Population

8. Exosome Therapies Marketed Drugs

• 8.1. Key Competitors
  • 8.1.1. Product Description
  • 8.1.2. Regulatory Milestones
  • 8.1.3. Other Developmental Activities
  • 8.1.4. Ongoing Clinical Development
  • 8.1.5. Safety and Efficacy

9. Exosome Therapies Emerging Drugs

• 9.1. Key Competitors
  • 9.1.1. Product Description
  • 9.1.2. Other Development Activities
  • 9.1.3. Clinical Development
    • 9.1.3.1. Clinical Trials Information
  • 9.1.4. Safety and Efficacy

10. Exosome Therapies: The 7MM Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Key Market Forecast Assumptions
• 10.4. Total Market Size of Exosome Therapies in the 7MM
  • 10.4.1. Market Size of Exosome Therapies By Therapies In the 7MM
  • 10.4.2. Market Size of Exosome Therapies By Indication In the 7MM
• 10.6. United States Market
  • 10.6.1. Total Market Size of Exosome Therapies in the United States
  • 10.6.2. Market Size of Exosome Therapies By Therapies in the United States
• 10.7. EU4 and the UK Market
  • 10.7.1. Total Market Size of Exosome Therapies in EU4 and the UK
  • 10.7.2. Market Size of Exosome Therapies By Therapies in EU4 and the UK
• 10.8. Japan Market
  • 10.8.1. Total Market Size of Exosome Therapies in Japan
  • 10.8.2. Market Size of Exosome Therapies By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

• 14.1. United States
  • 14.1.1. Centre for Medicare & Medicaid Services (CMS)
• 14.2. EU4 and the UK
  • 14.2.1. Germany
  • 14.2.2. France
  • 14.2.3. Italy
  • 14.2.4. Spain
  • 14.2.5. United Kingdom
• 14.3. Japan
  • 14.3.1. MHLW

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight